297-88-1

Usage

Uses

Used in Opioid Addiction Treatment:
Methadone is used as a therapeutic agent for the treatment of opioid addiction, particularly for individuals dependent on substances like heroin and narcotic painkillers. It helps in managing withdrawal symptoms and reducing cravings, thus facilitating the recovery process.
Used in Chronic Pain Management:
Methadone is used as an analgesic for the management of chronic pain. Its effectiveness in treating pain is due to its action on the opioid receptors in the brain, providing relief to patients suffering from long-term pain conditions.

Upstream product

• 10467-10-4 ethylmagnesium iodide 
• 125-79-1 (R,S)-2,2-diphenyl-4-dimethylaminopentanenitrile 
• 6336-52-3 1,1-diphenylbutan-2-one 
• 53309-35-6 (2-chloro-1-methyl-ethyl)-dimethyl-amine 
• 86-29-3 Diphenylacetonitrile 
• 76-99-3 Methadone 
• 7576-16-1 (R)-(-)-2,2-diphenyl-4-dimethylaminopentanenitrile 
• 925-90-6 ethylmagnesium bromide 
• 1095-90-5 methadone hydrochloride 
• 7576-08-1 (S)-(+)-2,2-diphenyl-4-dimethylaminopentanenitrile 
• 5967-73-7 (R)-methadone hydrochloride 

Downstream Products

• 13957-55-6 recipavrin 
• 30223-73-5 (R,S)-2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
• 15284-15-8 (+)-Methadone hydrochloride 

Relevant academic research and scientific papers

Simultaneous chiral separation of tramadol and methadone in tablets, human urine, and plasma by capillary electrophoresis using maltodextrin as the chiral selector

The stereoselective analysis and separation of racemic drugs play an important role in pharmaceutical industry to eliminate the unwanted isomer and find the right therapeutic control for the patient. Present study suggests a maltodextrin-modified capillary electrophoresis method for a single‐run chiral separation of two closely similar opiate pain relief drugs: tramadol (TRA) and methadone (MET). The best separation method possible for the both enantiomers was achieved on an uncoated fused‐silica capillary at 25°C using 100 mM phosphate buffer (pH 8.0) containing 20% (w v?1) maltodextrin with dextrose equivalent of 4–7 and an applied voltage of 16 kV. Under optimal conditions, the baseline resolution of TRA and MET enantiomers was obtained in less than 12 minutes. The relative standard deviations (n = 3) of 20 μg mL?1 TRA and MET were 2.28% and 3.77%, respectively. The detection limits were found to be 2 μg mL?1 for TRA and 1.5 μg mL?1 for MET. This method was successfully applied to the measurement of drugs concentration in their tablets, urine, and plasma samples.

Non-Racemic Mixtures of Various Ratios of D- and L-methadone and Methods of Treating Pain Using the Same

Non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, such as for example about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or about 3:1 by weight of D-methadone to L-methadone, have been found to exhibit surprising and unexpected beneficial results in the treatment of neuropathic pain. Additionally, non-racemic mixtures of D- and L-methadone containing a ratio ranging from about 2.5:1 to about 3.5:1 by weight of D-methadone to L-methadone, about 2.9:1 to about 3.1:1 by weight of D-methadone to L-methadone, or for example about 3:1 by weight of D-methadone to L-methadone, in combination with other non-methadone opioids have been found to exhibit surprising and unexpected beneficial results in the treatment of mixed pain.

"A NOVEL PROCESS FOR CHIRAL RESOLUTION OF HIGHLY PURE (6R)-6-(DIMETHYLAMINO)-4,4-DIPHENYL-3-HEPTANONE FROM RACEMIC METHADONE HYDROCHLORIDE"

The present invention discloses an improved process for preparing pure (dimethylarnino)-4,4-diphenyl-3-heptanone and its hydrochloride salt.

(R)-6-(DIMETHYLAMINO)-4,4-DIPHENYLHEPTAN-3-ONE

(R)-6-(dimethylamino)-4,4-diphenylheptan-3-one and a process to produce thereof.

(R)-6-(DIMETHYLAMINO)-4,4-DIPHENYLHEPTAN-3-ONE

Methods for producing methadone and its resolution to produce (R)-6-dimethylamino-4,4-diphenylheptan-3-one ((R)- methadone). Such methods producing first the precursor compound 4-(dimethylamino)-2,2-diphenylpentanitrile. Oxidation of 4-(dimethylamino)-2,2-diphenylpentanitrile with ethyl magnesium halide and hydrolysis with of the complex to form 6-dimethylamino-4,4-diphenylheptan-3-one. Resolution to the (R)-isomer is effected by reaction with a bromocamphor salt. Once isolated the (R)-isomer is crystallised.

Combination of selected opioids with muscarine antagonists for treating urinary incontinence

Active compound combinations of compounds of group A, particularly opioids, and compounds of group B, particularly anti-muscarine agents and other substances suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.

Quaternary ammonium immunogenic conjugates and immunoassay reagents

This invention relates to novel quaternary ammonium immunogenic conjugates and reporter reagents useful for eliciting antibodies and in immunoassays. Processes for preparing such quaternary ammonium immunogenic conjugates and their use in immunoassays and in eliciting antibodies are also disclosed.

Radioimmunoassay for methadone

An improved immunoassay for methadone is disclosed. The subject radioimmunoassay utilizes a novel antigen, antibody and novel labelled methadone derivatives.